Abstract
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is associated with an increased risk of cardiovascular morbidity and mortality, especially due to ischemic stroke. The occurrence of AF leads to atrial electrical and structural remodeling. The renin-angiotensin system appears to play a role in the development of atrial arrhythmias by its involvement in both of these processes. Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 783-791 |
| Number of pages | 9 |
| Journal | Vascular Health and Risk Management |
| Volume | 5 |
| State | Published - Dec 1 2009 |
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Hematology
- Public Health, Environmental and Occupational Health
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
